Pause in Trading
Filed with ASX · · 1 page · English
Chimeric Therapeutics Limited on 6ix
Earlier from Chimeric Therapeutics
- Response to ASX Query Letter
- Additional complete responses in CHM CORE-NK Phase 1b trial
- Disease control and tumour shrinkage observed in CHM CDH17
- Appendix 4E and Annual Report
- CHM CDH17 Clinical Trial Update
Later from Chimeric Therapeutics
- CHM CORE NK Combination Phase 1b trial update
- 75% disease control observed in CHM CDH17 trial
- Chimeric receives $4.5M R&D tax incentive
- CDH17 granted FDA Orphan Drug Designation for Gastric Cancer
- Trading Halt
Follow Chimeric Therapeutics into a list and get an email when it puts out news.
Follow Chimeric Therapeutics